These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27144973)

  • 41. Suppression of tumor growth, invasion and angiogenesis of human gastric cancer by adenovirus-mediated expression of NK4.
    Heideman DA; van Beusechem VW; Bloemena E; Snijders PJ; Craanen ME; Offerhaus GJ; Derksen PW; de Bruin M; Witlox MA; Molenaar B; Meijer CJ; Gerritsen WR
    J Gene Med; 2004 Mar; 6(3):317-27. PubMed ID: 15026993
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antitumor activity, pharmacokinetics, tumor-homing effect, and hepatotoxicity of a species cross-reactive c-Met antibody.
    Park H; Kim D; Son E; Shin S; Sa JK; Kim SH; Yoon Y; Nam DH
    Biochem Biophys Res Commun; 2017 Dec; 494(1-2):409-415. PubMed ID: 28917835
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
    Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
    Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.
    O'Toole JM; Rabenau KE; Burns K; Lu D; Mangalampalli V; Balderes P; Covino N; Bassi R; Prewett M; Gottfredsen KJ; Thobe MN; Cheng Y; Li Y; Hicklin DJ; Zhu Z; Waltz SE; Hayman MJ; Ludwig DL; Pereira DS
    Cancer Res; 2006 Sep; 66(18):9162-70. PubMed ID: 16982759
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
    Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
    Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
    [TBL] [Abstract][Full Text] [Related]  

  • 46. YYB-101, a Humanized Antihepatocyte Growth Factor Monoclonal Antibody, Inhibits Ovarian Cancer Cell Motility and Proliferation.
    Kim HJ; Heo K
    Anticancer Res; 2021 Feb; 41(2):671-678. PubMed ID: 33517271
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both
    Wang J; Anderson MG; Oleksijew A; Vaidya KS; Boghaert ER; Tucker L; Zhang Q; Han EK; Palma JP; Naumovski L; Reilly EB
    Clin Cancer Res; 2017 Feb; 23(4):992-1000. PubMed ID: 27573171
    [No Abstract]   [Full Text] [Related]  

  • 48. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model.
    Sampson ER; Martin BA; Morris AE; Xie C; Schwarz EM; O'Keefe RJ; Rosier RN
    J Bone Miner Res; 2011 Jun; 26(6):1283-94. PubMed ID: 21308771
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo.
    van der Horst EH; Chinn L; Wang M; Velilla T; Tran H; Madrona Y; Lam A; Ji M; Hoey TC; Sato AK
    Neoplasia; 2009 Apr; 11(4):355-64. PubMed ID: 19308290
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth.
    Zhang YW; Staal B; Essenburg C; Su Y; Kang L; West R; Kaufman D; Dekoning T; Eagleson B; Buchanan SG; Vande Woude GF
    Cancer Res; 2010 Sep; 70(17):6880-90. PubMed ID: 20643778
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acquired Resistance to a MET Antibody
    Pollmann SE; Calvert VS; Rao S; Boca SM; Madhavan S; Horak ID; Kjaer A; Petricoin EF; Kragh M; Poulsen TT
    Mol Cancer Ther; 2018 Jun; 17(6):1259-1270. PubMed ID: 29545332
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
    Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
    Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities.
    Wang Y; Zhan Z; Jiang X; Peng X; Shen Y; Chen F; Ji Y; Liu W; Shi Y; Duan W; Ding J; Ai J; Geng M
    Oncotarget; 2016 Jun; 7(25):38091-38104. PubMed ID: 27191264
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.
    Ahn SY; Kim J; Kim MA; Choi J; Kim WH
    Anticancer Res; 2017 Mar; 37(3):1127-1138. PubMed ID: 28314274
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms.
    Grandal MM; Havrylov S; Poulsen TT; Koefoed K; Dahlman A; Galler GR; Conrotto P; Collins S; Eriksen KW; Kaufman D; Woude GFV; Jacobsen HJ; Horak ID; Kragh M; Lantto J; Bouquin T; Park M; Pedersen MW
    Mol Cancer Ther; 2017 Dec; 16(12):2780-2791. PubMed ID: 28802255
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Green tea (-)-epigallocatechin-3-gallate inhibits HGF-induced progression in oral cavity cancer through suppression of HGF/c-Met.
    Koh YW; Choi EC; Kang SU; Hwang HS; Lee MH; Pyun J; Park R; Lee Y; Kim CH
    J Nutr Biochem; 2011 Nov; 22(11):1074-83. PubMed ID: 21292466
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Probing conformational and functional states of human hepatocyte growth factor by a panel of monoclonal antibodies.
    Umitsu M; Sakai K; Ogasawara S; Kaneko MK; Asaki R; Tamura-Kawakami K; Kato Y; Matsumoto K; Takagi J
    Sci Rep; 2016 Sep; 6():33149. PubMed ID: 27608665
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of the met receptor in mesothelioma.
    Mukohara T; Civiello G; Davis IJ; Taffaro ML; Christensen J; Fisher DE; Johnson BE; Jänne PA
    Clin Cancer Res; 2005 Nov; 11(22):8122-30. PubMed ID: 16299245
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antipodocalyxin Antibody chPcMab-47 Exerts Antitumor Activity in Mouse Xenograft Models of Colorectal Adenocarcinomas.
    Kaneko MK; Kunita A; Yamada S; Nakamura T; Yanaka M; Saidoh N; Chang YW; Handa S; Ogasawara S; Ohishi T; Abe S; Itai S; Harada H; Kawada M; Nishioka Y; Fukayama M; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Aug; 36(4):157-162. PubMed ID: 28665782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.